ABCL News and Press, AbCellera Biologics Inc. From 11/16/21

Stanley Druckenmiller's Duquesne disclosed its updated portfolio position in its recent 13F filing. It has taken new positions in Coupang (NYSE:CPNG) of 15.5M shares, Oscar Health (NYSE:OSCR) of 0.99M shares, AbCellera Biologics (NASDAQ:ABCL) of 0.66M shares and PROCEPT BioRobotics&...

Shares of antibody discoverer AbCellera Biologics Inc. (ABCL) have fallen 80% from their all-time high as the market has thoroughly discounted its COVID-19 assets. The pandemic showcased AbCellera’s discovery platform, but the speed to market and royalty participation percentag...

The following slide deck was published by AbCellera Biologics Inc. in conjunction with their 2021 Q3 earnings call. For further details see: AbCellera Biologics Inc. 2021 Q3 - Results - Earnings Call Presentation

Image source: The Motley Fool. AbCellera Biologics Inc. (NASDAQ: ABCL) Q3 2021 Earnings Call Nov 09, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics Inc. (ABCL) Q3 2021 Earnings Call Transcript ...

Abcellera Biologics, Inc. (ABCL) Q3 2021 Earnings Conference Call November 09, 2021, 17:00 ET Company Participants Tryn Stimart - Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Carl Hansen - President, CEO & Director Andrew Booth - CFO Conference Call Participants...

AbCellera Biologics (NASDAQ:ABCL): Q3 GAAP EPS of -$0.08 misses by $0.02. Revenue of $5.51M (-41.1% Y/Y) misses by $4.49M. Press Release For further details see: AbCellera Biologics EPS misses by $0.02, misses on revenue

Total revenue of $6 million, compared to $9 million in Q3 2020 Nine program starts in the quarter bringing cumulative total to 69, up 35% from Q3 2020 Net loss of ($0.08) per share (basic and diluted) compared to a net loss of ($0.02) per share (basic and diluted) in...

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following virtual investor conferences: Credit Suisse 30th Annual Virtual Healthcare Conference on Thursday, November 11 at 7:30 a.m. Pacific Time Stifel 2021 Virtual Healthcare C...

Shares of AbCellera Biologics (NASDAQ: ABCL) fell 21.6% in October, according to data from S&P Global Market Intelligence . The biotech declined in response to news that an experimental pill developed by Merck has been shown to cut the risk of COVID-19-related hospitaliz...

AbCellera (Nasdaq: ABCL) today announced an additional purchase by the U.S. government from Eli Lilly and Company (Lilly) for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is authorized for emergency use for the treatment of mild to mod...